Development of an RT-LAMP assay for the detection of Lassa viruses in southeast and south-central Nigeria.

Authors:
Yohei Kurosaki
Yohei Kurosaki
National Research Institute of Police Science
Japan
Rokusuke Yoshikawa
Rokusuke Yoshikawa
Laboratory of Signal Transduction
Olamide K Oloniniyi
Olamide K Oloniniyi
Institute of Tropical Medicine (NEKKEN)
Shuzo Urata
Shuzo Urata
National Research Institute of Police Science
Japan
Vahid R Zadeh
Vahid R Zadeh
Regional Reference Laboratory for Influenza Virus & ICMR Grade-I Virus Diagnostic Laboratory

J Virol Methods 2019 Jul 8;269:30-37. Epub 2019 Apr 8.

Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan; Graduate School of Biomedical Sciences and Program for Nurturing Global Leaders in Tropical and Emerging Communicable Diseases, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan; National Research Center for the Control and Prevention of Infectious Diseases (CCPID), Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan. Electronic address:

Lassa virus (LASV) causes Lassa fever (LF), a viral hemorrhagic fever endemic in West Africa. LASV strains are clustered into six lineages according to their geographic location. To confirm a diagnosis of LF, a laboratory test is required. Here, a reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay using a portable device for the detection of LASV in southeast and south-central Nigeria using three primer sets specific for strains clustered in lineage II was developed. The assay detected in vitro transcribed LASV RNAs within 23 min and was further evaluated for detection in 73 plasma collected from suspected LF patients admitted into two health settings in southern Nigeria. The clinical evaluation using the conventional RT-PCR as the reference test revealed a sensitivity of 50% in general with 100% for samples with a viral titer of 9500 genome equivalent copies (geq)/mL and higher. The detection limit was estimated to be 4214 geq/mL. The assay showed 98% specificity with no cross-reactivity to other viruses which cause similar symptoms. These results suggest that this RT-LAMP assay is a useful molecular diagnostic test for LF during the acute phase, contributing to early patient management, while using a convenient device for field deployment and in resource-poor settings.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jviromet.2019.04.010DOI Listing
July 2019
1 Read

Publication Analysis

Top Keywords

rt-lamp assay
12
south-central nigeria
8
southeast south-central
8
strains clustered
8
assay
5
nigeria clinical
4
clinical evaluation
4
southern nigeria
4
admitted health
4
patients admitted
4
health settings
4
settings southern
4
rt-pcr reference
4
sensitivity 50%
4
50% general
4
general 100%
4
revealed sensitivity
4
test revealed
4
conventional rt-pcr
4
suspected patients
4

Similar Publications